CSL Limited

ASX:CSL.AX

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

🔍 Research & Consulting

Location

Australia

Market Cap

USD 75.68 B

Share Price

USD 156.33

Avg Daily Volume

902,529

Change (1 day)

0.91%

Change (1 year)

-19.21%

Change (YTD)

-10.30%

CSL Limited EPS (Diluted) for the year ending June 30, 2024: USD 5.45

CSL Limited EPS (Diluted) is USD 5.45 for the year ending June 30, 2024, a -20.90% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

CSL Limited EPS (Diluted) for the year ending June 30, 2023 was USD 6.89, a 4.24% change year over year.
CSL Limited EPS (Diluted) for the year ending June 30, 2022 was USD 6.61, a 26.15% change year over year.
CSL Limited EPS (Diluted) for the year ending June 30, 2021 was USD 5.24, a 9.85% change year over year.
CSL Limited EPS (Diluted) for the year ending June 30, 2020 was USD 4.77, a 15.50% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Selling, General, and Administrative Expenses (SG&A)	Research and Development (R&D) Expenses

ASX: CSL.AX

CSL Limited

CEO	Dr. Paul F. McKenzie Ph.D.
IPO Date	June 1, 1994
Location	Australia
Headquarters	45 Poplar Road
Employees	32,698
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals 🔍 Research & Consulting

Description

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.